Jim Simons Biotechnology

Renaissance Technologies LLC

$63.4 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
KOD Kodiak Sciences Inc.	$151M	$4.59 Million 0.01% of portfolio	461,600	Q4 2024 Reduced 24.05%
PCVX Vaxcyte, Inc.	$4.12B	$4.43 Million 0.01% of portfolio	54,077	Q4 2024 New
MIRM Mirum Pharmaceuticals, Inc.	$1.69B	$4.19 Million 0.01% of portfolio	101,248	Q4 2024 Added 67.5%
MREO Mereo Biopharma Group PLC	$297M	$4.16 Million 0.01% of portfolio	1,189,471	Q4 2024 Reduced 8.88%
BCRX Biocryst Pharmaceuticals Inc	$1.46B	$4.1 Million 0.01% of portfolio	545,021	Q4 2024 Reduced 7.48%
AVIR Atea Pharmaceuticals, Inc.	$244M	$4.08 Million 0.01% of portfolio	1,216,600	Q4 2024 Added 0.79%
CDXC Chroma Dex Corp.	$463M	$3.78 Million 0.01% of portfolio	712,788	Q4 2024 Added 68.03%
BCYC Bicycle Therapeutics PLC	$266M	$3.77 Million 0.01% of portfolio	269,500	Q4 2024 Reduced 1.14%
ACLX Arcellx, Inc.	$2.98B	$3.74 Million 0.01% of portfolio	49,100	Q4 2024 New
NKTR Nektar Therapeutics	$139M	$3.64 Million 0.01% of portfolio	3,910,786	Q4 2024 Added 17.52%
TERN Terns Pharmaceuticals, Inc.	$110M	$3.48 Million 0.01% of portfolio	623,134	Q4 2024 Added 29.95%
CLDX Celldex Therapeutics, Inc.	$932M	$3.45 Million 0.01% of portfolio	136,588	Q4 2024 New
IMNM Immunome Inc.	$84.8M	$3.24 Million 0.01% of portfolio	316,000	Q4 2024 Added 2,696.46%
SGMO Sangamo Therapeutics, Inc	$128M	$3.15 Million 0.0% of portfolio	3,084,877	Q4 2024 Reduced 36.43%
DAWN Day One Biopharmaceuticals, Inc.	$593M	$3.09 Million 0.0% of portfolio	243,740	Q4 2024 Added 157.0%
CNTA Centessa Pharmaceuticals PLC	$1.38B	$2.99 Million 0.0% of portfolio	178,600	Q4 2024 Reduced 14.79%
TRDA Entrada Therapeutics, Inc.	$300M	$2.87 Million 0.0% of portfolio	166,200	Q4 2024 Added 77.19%
ENTA Enanta Pharmaceuticals Inc	$118M	$2.86 Million 0.0% of portfolio	498,000	Q4 2024 Reduced 5.12%
CMRX Chimerix Inc	$745M	$2.85 Million 0.0% of portfolio	820,349	Q4 2024 Reduced 38.75%
IMCR Immunocore Holdings PLC	$1.3B	$2.85 Million 0.0% of portfolio	96,570	Q4 2024 Reduced 65.04%
ERAS Erasca, Inc.	$186M	$2.84 Million 0.0% of portfolio	1,133,000	Q4 2024 Reduced 12.24%
PRTA Prothena Corp Public LTD CO	$617M	$2.8 Million 0.0% of portfolio	201,900	Q4 2024 Added 10.45%
RCKT Rocket Pharmaceuticals, Inc.	$574M	$2.75 Million 0.0% of portfolio	218,519	Q4 2024 New
LQDA Liquidia Corp	$971M	$2.68 Million 0.0% of portfolio	228,000	Q4 2024 New
PSTX Poseida Therapeutics, Inc.	$815M	$2.6 Million 0.0% of portfolio	271,200	Q4 2024 Reduced 69.79%
ETON Eton Pharmaceuticals, Inc.	$329M	$2.54 Million 0.0% of portfolio	193,100	Q4 2024 Added 131.53%
ANNX Annexon, Inc.	$109M	$2.53 Million 0.0% of portfolio	493,700	Q4 2024 Added 22.99%
SAGE Sage Therapeutics, Inc.	$492M	$2.45 Million 0.0% of portfolio	450,795	Q4 2024 Reduced 12.18%
CGEM Cullinan Oncology, Inc.	$366M	$2.32 Million 0.0% of portfolio	190,508	Q4 2024 Reduced 32.4%
AVXL Anavex Life Sciences Corp.	$680M	$2.29 Million 0.0% of portfolio	213,200	Q4 2024 Reduced 12.55%
ETNB 89bio, Inc.	$376M	$2.28 Million 0.0% of portfolio	297,700	Q4 2024 Reduced 4.59%
IMVT Immunovant, Inc.	$3.55B	$2.23 Million 0.0% of portfolio	80,900	Q4 2024 Reduced 57.2%
PLX Protalix Bio Therapeutics, Inc.	$128M	$2.15 Million 0.0% of portfolio	1,118,000	Q4 2024 Added 16.96%
RGNX Regenxbio Inc.	$338M	$2.1 Million 0.0% of portfolio	271,300	Q4 2024 New
CRDF Cardiff Oncology, Inc.	$143M	$2.1 Million 0.0% of portfolio	483,090	Q4 2024 Reduced 19.8%
VERV Verve Therapeutics, Inc.	$313M	$2.05 Million 0.0% of portfolio	363,400	Q4 2024 Reduced 36.78%
CRVS Corvus Pharmaceuticals, Inc.	$157M	$2.03 Million 0.0% of portfolio	390,688	Q4 2024 Added 1.06%
ACIU Ac Immune Sa	$165M	$2 Million 0.0% of portfolio	740,198	Q4 2024 Added 14.58%
SRRK Scholar Rock Holding Corp	$1.7B	$1.98 Million 0.0% of portfolio	45,700	Q4 2024 Reduced 80.41%
LRMR Larimar Therapeutics, Inc.	$102M	$1.96 Million 0.0% of portfolio	513,542	Q4 2024 Added 45.13%
CGEN Compugen LTD	$132M	$1.95 Million 0.0% of portfolio	1,277,200	Q4 2024 Reduced 0.77%
SEER Seer, Inc.	$102M	$1.95 Million 0.0% of portfolio	843,700	Q4 2024 Added 27.04%
BDTX Black Diamond Therapeutics, Inc.	$58.5M	$1.93 Million 0.0% of portfolio	904,000	Q4 2024 Added 256.19%
REPL Replimune Group, Inc.	$512M	$1.9 Million 0.0% of portfolio	156,936	Q4 2024 Added 45.67%
COGT Cogent Biosciences, Inc.	$426M	$1.89 Million 0.0% of portfolio	242,929	Q4 2024 New
NKTX Nkarta, Inc.	$97.3M	$1.89 Million 0.0% of portfolio	757,075	Q4 2024 Reduced 14.38%
STRO Sutro Biopharma, Inc.	$38.6M	$1.87 Million 0.0% of portfolio	1,015,211	Q4 2024 Added 22.6%
VRCA Verrica Pharmaceuticals Inc.	$327M	$1.85 Million 0.0% of portfolio	233,300	Q4 2024 Added 57.67%
EDIT Editas Medicine, Inc.	$85.9M	$1.84 Million 0.0% of portfolio	1,451,049	Q4 2024 New
HRTX Heron Therapeutics, Inc.	$268M	$1.82 Million 0.0% of portfolio	1,188,800	Q4 2024 Reduced 40.8%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account